TALVEY® (talquetamab-tgvs) is the first and only FDA-approved bispecific antibody that targets GPRC5D for the treatment of relapsed or refractory multiple myeloma
CD, cluster of differentiation; FDA, U.S. Food and Drug Administration; GPRC5D, G protein-coupled receptor class C group 5 member D; HCP, healthcare provider; REMS, Risk Evaluation and Mitigation Strategy.